Viral clearance during the manufacture of urokinase from human urine

Biotechnology and Bioprocess Engineering

Volumn 13, Issue 1, 2008, Pages 25-32

  Choi, Yong Woon ^a,b   Kim, In Seop ^c  

^a Green Cross Company   (South Korea)

^b Ajou University   (South Korea)

^c Hannam University   (South Korea)

Author keywords

Log reduction factor; Urokinase; Viral clearance; Virus safety

Indexed keywords

4 AMINOBENZAMIDINE; UROKINASE;

AFFINITY CHROMATOGRAPHY; ARTICLE; BIOTECHNOLOGICAL PROCEDURES; BIOTECHNOLOGICAL PRODUCTION; BOVINE DIARRHEA VIRUS; BOVINE HERPES VIRUS; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CULTURE TECHNIQUE; ENZYME SYNTHESIS; FILTRATION; FREEZE DRYING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; PASTEURIZATION; URINARY EXCRETION; VIRUS INACTIVATION; VIRUS INHIBITION;

BOVINAE; BOVINE VIRAL DIARRHEA VIRUS 1; ENCEPHALOMYOCARDITIS VIRUS; HERPESVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS; MURINAE;

EID: 40549106492     PISSN: 12268372     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12257-007-0140-7     Document Type: Article

References (24)

1. Sherry, S. (1987) Thrombolytic therapy in acute myocardial infarction. A perspective. Drugs 33: S1-S12.
2. Bansal, V. and P. K. Roychoudhury (2006) Production and purification of urokinase: a comprehensive review. Protein Expr. Purif. 45: 1-14.
3. Bennion, D. W., L. J. Wright, R. A. Watt, A. A. Whiting, and J. F. Carlquist (1998) Optimal recovery of cytomegalovirus from urine as a function of specimen preparation. Diagn. Microbiol. Infect. Dis. 31: 337-342.
4. Coulepis, A. G., S. A. Locarnini, N. I. Lehmann, and I. D. Gust (1980) Detection of hepatitis A virus in the feces of patients with naturally acquired infections. J. Infect. Dis. 141: 151-156.
5. Melchers, W. J., R. Schift, E. Stolz, J. Lindeman, and W. G. Quint (1989) Human papillomavirus detection in urine samples from male patients by the polymerase chain reaction. J. Clin. Microbiol. 27: 1711-1714.
6. Schalasta, G., M. Eggers, M. Schmid, and G. Enders (2000) Analysis of human cytomegalovirus DNA in urines of newborns and infants by means of a new ultrarapid real-time PCR-system. J. Clin. Virol. 19: 175-185.
7. Kim, I. S., Y. W. Choi, S. R. Lee, Y. Kang, K. M. Lee, D. H. Park, H. S. Woo, and S. Lee (2002) Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine. Biotechnol. Bioprocess Eng. 7: 340-346.
8. Kim, I. S., Y. W. Choi, and S. R. Lee (2004) Optimization and validation of a virus filtration process for efficient removal of viruses from urokinase solution prepared from human urine. J. Microbiol. Biotechnol. 14: 140-147.
9. Committee for Proprietary Medicinal Products (CPMP), The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluaation Unit (1996) Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP/BWP/268/95).
10. International Conference on Harmonisation (1998) Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; Availability. Federal Resister 63: 51074-51084.
11. Kim, I. S., Y. W. Choi, S. R. Lee, and H. M. Sung (2004) Cold ethanol fractionation and heat inactivation of hepatitis A virus during manufacture of albumin from human plasma. Biotechnol. Bioprocess Eng. 9: 65-68.
12. Shin, J. S., Y. W. Choi, H. M. Sung, Y. W. Ryu, and I. S. Kim (2006) Enhanced virus safety of a solvent/detergent-treated antihemophilic factor IX concentrate by dry-heat treatment. Biotechnol. Bioprocess Eng. 11: 19-25.
13. Kim, I. S., Y. W. Choi, H. S. Woo, C. E. Chang, and S. Lee (2000) Solvent/detergent inactivation and chromatographic removal of human immunodeficiency virus during the manufacturing of a high purity antihemophilic factor VIII concentrate. J. Microbiol. 38: 187-191.
14. Kim, I. S., Y. W. Choi, S. R. Lee, H. S. Woo, and S. Lee (2001) Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. Biotechnol. 11: 497-503.
15. Kärber, J. (1931) Beitrag zur kollectiven Behandlung pharmakologische Reihenversuche. Arch. Exp. Path. Pharmakol. 162: 480-483.
16. Aranha, H. (2001) Viral clearance strategies for biopharmaceutical safety. Part 1: General considerations. Bio. Pharm. January: 28-35.
17. Josić, D., P. Schulz, L. Biesert, L. Hoffer, H. Schwinn, M. Kordis-Krapez, and A. Strancar (1997) Issues in the development of medical products based on human plasma. J. Chromatogr. B 694: 253-269.
18. Kim, I. S. (2004) Improvement of parvovirus safety of a human urokinase by a virus filtration process. J. Sci. Inst. Han Nam Univ. 34: 31-40.
19. Brorson, K., J. Brown, E. Hamilton, and K. E. Stein (2003) Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use. J. Chromatogr. A 989: 155-163.
20. Aranha, H. (2001) Viral clearance strategies for biopharmaceutical safety. Part 2: Filtration for viral clearance. Bio. Pharm. February: 32-43.
21. Schmidt, S., J. Mora, S. Dolan, and J. Kauling (2005) An integrated concept for robust and efficient virus clearance and contaminant removal in biotech processes. BioProcess Int. 3: 26-31.
22. Remington, K. M., S. R. Trejo, G. Buczynski, H. Li, W. P. Osheroff, J. P. Brown, H. Renfrow, R. Reynolds, and D. Y. Pifat (2004) Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products. Vox. Sang. 87: 10-18.
23. Kim, I. S., H. G. Eo, C. E. Chang, and S. Lee (2000) Partitioning and inactivation of viruses by cold ethanol fractionation and pasteurization during manufacture of albumin from human plasma. J. Microbiol. Biotechnol. 10: 858-864.
24. Kim, I. S., H. G. Eo, C. W. Park, C. E. Chang, and S. Lee (2001) Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacture of albumin and immunoglobulins from human plasma. Biotechnol. Bioprocess Eng. 6: 25-30.